| First Author | Diepstraten ST | Year | 2024 |
| Journal | Cancer Cell | Volume | 42 |
| Issue | 5 | Pages | 850-868.e9 |
| PubMed ID | 38670091 | Mgi Jnum | J:349458 |
| Mgi Id | MGI:7641190 | Doi | 10.1016/j.ccell.2024.04.004 |
| Citation | Diepstraten ST, et al. (2024) Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell 42(5):850-868.e9 |
| abstractText | TP53-mutant blood cancers remain a clinical challenge. BH3-mimetic drugs inhibit BCL-2 pro-survival proteins, inducing cancer cell apoptosis. Despite acting downstream of p53, functional p53 is required for maximal cancer cell killing by BH3-mimetics through an unknown mechanism. Here, we report p53 is activated following BH3-mimetic induced mitochondrial outer membrane permeabilization, leading to BH3-only protein induction and thereby potentiating the pro-apoptotic signal. TP53-deficient lymphomas lack this feedforward loop, providing opportunities for survival and disease relapse after BH3-mimetic treatment. The therapeutic barrier imposed by defects in TP53 can be overcome by direct activation of the cGAS/STING pathway, which promotes apoptosis of blood cancer cells through p53-independent BH3-only protein upregulation. Combining clinically relevant STING agonists with BH3-mimetic drugs efficiently kills TRP53/TP53-mutant mouse B lymphoma, human NK/T lymphoma, and acute myeloid leukemia cells. This represents a promising therapy regime that can be fast-tracked to tackle TP53-mutant blood cancers in the clinic. |
